<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="193274">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00576069</url>
  </required_header>
  <id_info>
    <org_study_id>20070934</org_study_id>
    <nct_id>NCT00576069</nct_id>
  </id_info>
  <brief_title>Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma</brief_title>
  <official_title>Evaluation of Mechanism(s)Limiting Expiratory Airflow in Chronic, Stable Asthmatics Who Are Non-smokers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gelb, Arthur F., M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gelb, Arthur F., M.D.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the site and mechanisms responsible for expiratory
      airflow limitation in chronic, treated, non-smoking, stable asthmatics with moderate to
      severe persistent expiratory airflow obstruction. Treatment will include inhaled
      corticosteroids and long acting beta2agonists and long acting muscarinic antagonists. We are
      interested in determining whether the large and/or small airways are the predominant site of
      airflow limitation. We are also interested in determining whether intrinsic small airways
      obstruction and/or loss of lung elastic recoil is responsible for expiratory airflow
      limitation and to what extent may be attributed to loss of lung elastic recoil vs decreased
      airway conductance in peripheral airways. We are also interested to evaluate the role of
      varying doses of inhaled corticosteroids to suppress large and small airway inflammation
      using exhaled nitric oxide as surrogate markers of inflammation. For comparison purposes,
      spirometry and measurements of exhaled nitric oxide will also be obtained if possible during
      a naturally occurring exacerbation of asthma. High resolution thin section CT of the lung
      will also be obtained. Analysis will evaluate integrity of the lung parenchyma as to absence
      and or presence of emphysema and extent of emphysema using voxel quantification. We will
      also investigate optical coherence tomography to detect clinically unsuspected emphysema. We
      will also obtain autopsy material when available in asthmatics who expire
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Results will be evaluated during exacerbation and when stable following treatment.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>use exhaled nitric oxide as a surrogate marker of large airway vs small airway/lung inflammation following various doses of inhaled corticosteroids</measure>
    <time_frame>20-60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>determine site of airflow limitation, whether predominantly large and /or small airways using expiratory flow volume curves obtained before and after asthmatics breathe a 80% helium-20% oxygen gas mixture</measure>
    <time_frame>20-60 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>investigate the mechanisms that limit expiratory airflow: intrinsic airway obstruction vs loss of lung elastic recoil</measure>
    <time_frame>20-60 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>dynamic hyperinflation</measure>
    <time_frame>20-60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate large and small airways and lung parenchyma in autopsied asthmatics and look for unsuspected emphysema</measure>
    <time_frame>June 2015</time_frame>
    <description>If approved by surviving power of attorney, chronic non-smoking asthmatics who expire will undergo autopsy evaluation to evaluate extent of airway obstruction as well as presence of emphysema</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optical Coherence Tomography</measure>
    <time_frame>June 2015</time_frame>
    <description>When stable, chronic non-smoking asthmatics with persistent expiratory airflow obstruction will undergo OCT via flexible bronchoscopy to detect unsuspected emphysema.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>asthma, quality of life, lung function</arm_group_label>
    <description>low or medium dose of inhaled fluticasone or equivalent corticosteroid 200-500mcg/day plus salmeterol 100 mcg/day or formoterol 24 mcg/day plus tiotropium 18ucg/day plus albuterol0.083%/ipratropium 0.02% or MDI for acute exacerbation.Will measure lung function and asthma quality of life questionaire</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>budesonide/formoterol</intervention_name>
    <description>budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or budesonide 160ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days</description>
    <arm_group_label>asthma, quality of life, lung function</arm_group_label>
    <other_name>symbicort 80/4.5</other_name>
    <other_name>symbicort 160/4.5</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluticasone/salmeterol</intervention_name>
    <description>fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid</description>
    <arm_group_label>asthma, quality of life, lung function</arm_group_label>
    <other_name>advair 100/50</other_name>
    <other_name>advair 250/50</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mometasone/formoterol</intervention_name>
    <description>200/5 mcg two puffs bid</description>
    <arm_group_label>asthma, quality of life, lung function</arm_group_label>
    <other_name>Dulera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>0-15 mg daily as needed</description>
    <arm_group_label>asthma, quality of life, lung function</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic Asthmatics
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Current non-smoking (&lt;10 pack yr smoking history)

          -  Stable, treated asthmatics

          -  Age 12-95 yr

          -  post 180ug albuterol by MDI: FEV 1/FVC &lt; 70% and FEV 1 &lt;80% predicted

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arthur F Gelb, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Arthur F Gelb Medical Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arthur F Gelb, MD</last_name>
    <phone>562-633-2204</phone>
    <email>afgelb@msn.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arthur F Gelb Medical Corporation</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90712</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arthur F Gelb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gelb AF, Zamel N. Unsuspected pseudophysiologic emphysema in chronic persistent asthma. Am J Respir Crit Care Med. 2000 Nov;162(5):1778-82.</citation>
    <PMID>11069812</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Licuanan J, Shinar CM, Zamel N. Unsuspected loss of lung elastic recoil in chronic persistent asthma. Chest. 2002 Mar;121(3):715-21.</citation>
    <PMID>11888951</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Gutierrez CA, Weisman IM, Newsom R, Taylor CF, Zamel N. Simplified detection of dynamic hyperinflation. Chest. 2004 Dec;126(6):1855-60.</citation>
    <PMID>15596684</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Flynn Taylor C, Shinar CM, Gutierrez C, Zamel N. Role of spirometry and exhaled nitric oxide to predict exacerbations in treated asthmatics. Chest. 2006 Jun;129(6):1492-9.</citation>
    <PMID>16778266</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Taylor CF, Nussbaum E, Gutierrez C, Schein A, Shinar CM, Schein MJ, Epstein JD, Zamel N. Alveolar and airway sites of nitric oxide inflammation in treated asthma. Am J Respir Crit Care Med. 2004 Oct 1;170(7):737-41. Epub 2004 Jun 30.</citation>
    <PMID>15229098</PMID>
  </reference>
  <reference>
    <citation>Gelb AF, Zamel N, Krishnan A. Physiologic similarities and differences between asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2008 Jan;14(1):24-30. Review.</citation>
    <PMID>18043272</PMID>
  </reference>
  <results_reference>
    <citation>Gelb AF, Moridzadeh R, Singh DH, Fraser C, George SC. In moderate-to-severe asthma patients monitoring exhaled nitric oxide during exacerbation is not a good predictor of spirometric response to oral corticosteroid. J Allergy Clin Immunol. 2012 Jun;129(6):1491-8. doi: 10.1016/j.jaci.2012.03.036. Epub 2012 May 2.</citation>
    <PMID>22560478</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Yamamoto A, Mauad T, Kollin J, Schein MJ, Nadel JA. Unsuspected mild emphysema in nonsmoking patients with chronic asthma with persistent airway obstruction. J Allergy Clin Immunol. 2014 Jan;133(1):263-5.e1-3. doi: 10.1016/j.jaci.2013.09.045. Epub 2013 Nov 28. Erratum in: J Allergy Clin Immunol. 2014 Apr;133(4):1232.</citation>
    <PMID>24290280</PMID>
  </results_reference>
  <results_reference>
    <citation>Gelb AF, Singh DH, Moridzadeh R, Fraser C, Tran D, Verbanck S, George SC. Age-stratified comparison of large and peripheral airway/alveolar nitric oxide levels in children and young adults. J Allergy Clin Immunol. 2013 Nov;132(5):1222-4. doi: 10.1016/j.jaci.2013.05.045. Epub 2013 Aug 6.</citation>
    <PMID>23932460</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>March 13, 2015</lastchanged_date>
  <firstreceived_date>December 17, 2007</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Gelb, Arthur F., M.D.</investigator_affiliation>
    <investigator_full_name>Arthur F Gelb MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>asthma</keyword>
  <keyword>lung function</keyword>
  <keyword>inflammation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
